Ji Hoon Lee

Ji Hoon Lee

Auto-generated profile, based on publicly available information

Ji Hoon Lee

Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
JHJuyeong Hong
Juyeong Hong
KXKexin Xu
Kexin Xu
JLJi Hoon Lee
Ji Hoon Lee
The N6-Methyladenosine (m6A) modification of RNA transcripts is the most prevalent and abundant internal modification in eukaryotic messenger RNAs (mRNAs) and plays diverse and important roles in normal biological processes. Extensive studies have indicated that dysregulated m6A modification and m6A-associated proteins play critical roles in tumorigenesis and cancer progression. However, m6A-mediated physiological consequences often lead to opposite outcomes in a biological context-dependent manner. Therefore, context-related complexity must be meaningfully considered to obtain a comprehensive understanding of RNA methylation. Recently, it has been reported that m6A-modified RNAs are closely related to the regulation of the DNA damage response and genomic integrity maintenance. Here, we present an overview of the current knowledge on the m6A modification and its function in human cancer, particularly in relation to the DNA damage response and genomic instability.

14 January 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YLYiji Liao
Yiji Liao
CCChen-Hao Chen
Chen-Hao Chen
TXTengfei Xiao
Tengfei Xiao
BABárbara de la Peña Avalos
Bárbara de la Peña Avalos
EDEloise Dray
Eloise Dray
KXKexin Xu
Kexin Xu
Significance: We identified a group of DNA repair genes directly induced by EZH2 and repressed by EZH2 inhibitors. Expression of these genes predicts the response of wild-type EZH2-harboring solid tumors to EZH2 inhibitors. Most importantly, our findings lay the foundation for the development of a combination therapy that combines EZH2 inhibitors and DNA damaging agents or drugs that block DNA repair for the treatment of castration-resistant prostate cancer and other solid tumors.

30 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
JLJi Hoon Lee
Ji Hoon Lee
JHJuyeong Hong
Juyeong Hong
ZZZhao Zhang
Zhao Zhang
BABárbara de la Peña Avalos
Bárbara de la Peña Avalos
CPCecilia J. Proietti
Cecilia J. Proietti
KXKexin Xu
Kexin Xu
Down-regulation of HMBOX1 via METTL3-catalyzed m 6 A causes genomic instability driven by telomere dysfunction in cancer.

12 October 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JHJuyeong Hong
Juyeong Hong
JLJi Hoon Lee
Ji Hoon Lee
ZZZhao Zhang
Zhao Zhang
YWYanming Wu
Yanming Wu
MYMei Yang
Mei Yang
KXKexin Xu
Kexin Xu
The immunosuppressive tumor microenvironment in some cancer types, such as luminal breast cancer, supports tumor growth and limits therapeutic efficacy. Identifying approaches to induce an immunostimulatory environment could help improve cancer treatment. Here, we demonstrate that inhibition of cancer-intrinsic EZH2 promotes antitumor immunity in estrogen receptor α–positive (ERα+) breast cancer. EZH2 is a component of the polycomb-repressive complex 2 (PRC2) complex, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3). A 53-gene PRC2 activity signature was closely associated with the immune responses of ERα+ breast cancer cells. The stimulatory effects of EZH2 inhibition on immune surveillance required specific activation of type I IFN signaling. Integrative analysis of PRC2-repressed genes and genome-wide H3K27me3 landscape revealed that type I IFN ligands are epigenetically silenced by H3K27me3. Notably, the transcription factor STAT2, but not STAT1, mediated the immunostimulatory functions of type I IFN signaling. Following EZH2 inhibition, STAT2 was recruited to the promoters of IFN-stimulated genes even in the absence of the cytokines, suggesting the formation of an autocrine IFN-STAT2 axis. In patients with luminal breast cancer, high levels of EZH2 and low levels of STAT2 were associated with the worst antitumor immune responses. Collectively, this work paves the way for the development of an effective therapeutic strategy that may reverse immunosuppression in cancer. Significance: Inhibition of EZH2 activates a type I IFN-STAT2 signaling axis and provides a therapeutic strategy to stimulate antitumor immunity and therapy responsiveness in immunologically cold luminal breast cancer.

5 March 2026 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JLJi Hoon Lee
Ji Hoon Lee
Mark TingeyMark Tingey
Mark Tingey
ZZZhao Zhang
Zhao Zhang
FBFlorian Buerger
Florian Buerger
JHJuyeong Hong
Juyeong Hong
KXKexin Xu
Kexin Xu

28 February 2015 in Asia-pacific Journal of Multimedia Services Convergent with Art, Humanities, and Sociology
Verified
Journal Article
Open access
JLJi Hoon Lee
Ji Hoon Lee